OncoMatch/Clinical Trials/NCT06102525
A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 With Valganciclovir (VGCV) in Subjects With Glioblastoma
Is NCT06102525 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including RZ-001 and VGCV for glioblastoma.
Treatment: RZ-001 · VGCV — This is a Phase 1/2a, open-label study to evaluate the safety, tolerability, immunogenicity, and preliminary clinical activity of RZ-001 administered in combination with VGCV in subjects with hTERT-positive GBM.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Glioblastoma
Biomarker criteria
Required: TERT positive expression (positive)
hTERT positive expression confirmed during the screening period
Disease stage
Grade: 4 (WHO)
Histologically-confirmed grade 4 astrocytoma, GBM, per The 2021 WHO Classification of CNS Tumors.
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06102525 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require TERT?
Yes, TERT positive expression is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages